Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery
- 40 Downloads
Population ageing in developed countries will inevitably increase the need for knee and hip replacement surgery. Over the years, direct oral anticoagulants, such as rivaroxaban, have been widely used for thromboprophylaxis in patients undergoing knee and hip replacement surgery. The study of pharmacogenetic characteristics of rivaroxaban is important for enhancing the effectiveness and safety of rivaroxaban thromboprophylaxis.
Evaluation of CYP3A4, CYP3A5 and ABCB1 gene polymorphisms influence on rivaroxaban pharmacokinetics and prothrombin time dynamics in patients undergoing total hip and knee replacement surgery.
The study included 78 patients undergoing total hip and knee replacement surgery. The patients received 10 mg of rivaroxaban once a day. Genotyping of polymorphisms ABCB1 rs1045642, ABCB1 rs4148738, CYP3A4 rs35599367 and CYP3A5 rs776746 was performed. Peak steady-state and trough steady-state rivaroxaban concentrations were determined. Prothrombin time was also evaluated.
The study revealed the following haplotypes: (1) ABCB1 rs1045642—CYP3A4 rs35599367 and (2) ABCB1 rs4148738—CYP3A4 rs35599367. The analysis of the peak steady-state rivaroxaban concentration between mutant haplotypes and wild haplotypes revealed no significant differences. However, there was a statistically significant average correlation between peak steady-state rivaroxaban concentration and prothrombin time (r = 0.421; r2 = 0.178; p < 0.001).
No significant difference was identified in peak steady-state rivaroxaban concentration between mutant haplotypes and wild haplotypes. The revealed statistically significant average correlation between the prothrombin time and peak steady-state rivaroxaban concentration is important in clinical practice for assessing the anticoagulant activity of rivaroxaban.
KeywordsRivaroxaban Pharmacogenetics Gene polymorphisms Drug concentration P-glycoprotein Thromboprophylaxis
This study was supported by Russian Science Foundation, project 16-15-00227 “Conducting fundamental scientific research and exploratory research on priority thematic research areas”. We would also like to thank all who participated in this study from Sechenov University’s Clinic of Traumatology, Orthopaedics and Joint Pathology, Department of Clinical Pharmacology and Propedeutics of Internal Diseases of Sechenov University and the R&D Center of Russian Medical Academy for Continuous Professional Education under the Ministry of Health of Russia.
Compliance with Ethical Standards
Conflict of interest
The authors have declared no conflict of interest.
- 2.Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. JBJS. LWW. 2007;89:780–5.Google Scholar
- 4.Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004;110:4. https://doi.org/10.1161/01.CIR.0000150639.98514.6c.CrossRefGoogle Scholar
- 5.Press Release of Johnson & Johnson. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery [Internet]. 2011 [cited 2019 Jun 13]. https://www.jnj.com/media-center/press-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery.
- 6.European Medicines Agency. CHMP assessment report for Xarelto [Internet]. 2008 [cited 2019 Jun 13]. https://www.ema.europa.eu/en/documents/assessment-report/xarelto-epar-public-assessment-report_en.pdf.
- 7.Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug metabolism and disposition. ASPET. 2009;37:1056–64.Google Scholar
- 8.Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British journal of clinical pharmacology. Wiley Online Library; 2013;76:455–66.Google Scholar
- 9.Online Encyclopedia for Genetic Epidemiology studies. Hardy-Weinberg equilibrium calculator [Internet]. 2008 [cited 2019 Jun 14]. http://www.oege.org/software/hwe-mr-calc.shtml.
- 10.Scitable by Nature Education: online educational resource for undergraduate biology students and educators. Haplotype / haplotypes [Internet]. [cited 2019 Aug 9]. https://www.nature.com/scitable/definition/haplotype-haplotypes-142/.
- 11.Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis. Wiley Online Library; 2017;15:273–83.Google Scholar
- 12.Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemostasis. 2008;100:453–61.CrossRefGoogle Scholar